Limits...
Epidemiology of prostate cancer in South Korea.

Han HH, Park JW, Na JC, Chung BH, Kim CS, Ko WJ - Prostate Int (2015)

Bottom Line: In South Korea, PCa incidence has increased significantly, while its mortality rate has decreased steadily.PCa incidence increased significantly faster in men aged < 70 years than in the older age group.PCa prevalence in South Korea has increased significantly, mainly due to the rise in its incidence.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, National Health Insurance Service Ilsan Hospital, Yonsei University College of Medicine, Goyang, South Korea.

ABSTRACT

Background: Prostate cancer (PCa) is the second most frequently diagnosed cancer in male. In South Korea, PCa incidence has increased significantly, while its mortality rate has decreased steadily. To optimize the distribution of public medical resources, it is essential to analyze the contemporary epidemiology of PCa.

Methods: National population data from the National Health Insurance Statistical Yearbook and the annual report of national cancer registration and statistics in Korea were assessed. From the data, the incidence, prevalence, and mortality rates of PCa were calculated. The data were presented with reference to other types of cancers occurring in various countries from different continents.

Results: From 2007 to 2013, PCa incidence doubled (from 5,516 per year to 10,855 per year), while its prevalence in Korean men tripled (from 18,830 to 51,411) during the same period. The mortality rate increased slightly, from 4.2 in 2000 to 5.9 in 2007 and 6.0 in 2013 (per 100,000, age adjusted). PCa incidence increased significantly faster in men aged < 70 years than in the older age group.

Conclusion: PCa prevalence in South Korea has increased significantly, mainly due to the rise in its incidence. As the country is facing major changes, including westernization of dietary habits and rapid population aging, its prevalence would continue to increase in near future.

No MeSH data available.


Related in: MedlinePlus

Cancer prevalence/5-year cancer prevalence of major sites in male, 2012. Age was adjusted to the Korean standard population. Original data available from the annual report of cancer statistics in Korea in 2012. ASR, age-standardized rate.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4588371&req=5

fig4: Cancer prevalence/5-year cancer prevalence of major sites in male, 2012. Age was adjusted to the Korean standard population. Original data available from the annual report of cancer statistics in Korea in 2012. ASR, age-standardized rate.

Mentions: Cancer prevalence rates among Korean men from January 1, 1999 to December 31, 2012 were calculated. The PCa prevalence rate (CR) was 194.6 per 100,000, ranking third after stomach and colorectal cancers (Fig. 4). The 5-year prevalence rate of PCa (CR) was 140.1 per 100,000, also ranking third after stomach and colorectal cancers. Since 2007, the PCa prevalence rate has increased gradually (Fig. 5).


Epidemiology of prostate cancer in South Korea.

Han HH, Park JW, Na JC, Chung BH, Kim CS, Ko WJ - Prostate Int (2015)

Cancer prevalence/5-year cancer prevalence of major sites in male, 2012. Age was adjusted to the Korean standard population. Original data available from the annual report of cancer statistics in Korea in 2012. ASR, age-standardized rate.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4588371&req=5

fig4: Cancer prevalence/5-year cancer prevalence of major sites in male, 2012. Age was adjusted to the Korean standard population. Original data available from the annual report of cancer statistics in Korea in 2012. ASR, age-standardized rate.
Mentions: Cancer prevalence rates among Korean men from January 1, 1999 to December 31, 2012 were calculated. The PCa prevalence rate (CR) was 194.6 per 100,000, ranking third after stomach and colorectal cancers (Fig. 4). The 5-year prevalence rate of PCa (CR) was 140.1 per 100,000, also ranking third after stomach and colorectal cancers. Since 2007, the PCa prevalence rate has increased gradually (Fig. 5).

Bottom Line: In South Korea, PCa incidence has increased significantly, while its mortality rate has decreased steadily.PCa incidence increased significantly faster in men aged < 70 years than in the older age group.PCa prevalence in South Korea has increased significantly, mainly due to the rise in its incidence.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, National Health Insurance Service Ilsan Hospital, Yonsei University College of Medicine, Goyang, South Korea.

ABSTRACT

Background: Prostate cancer (PCa) is the second most frequently diagnosed cancer in male. In South Korea, PCa incidence has increased significantly, while its mortality rate has decreased steadily. To optimize the distribution of public medical resources, it is essential to analyze the contemporary epidemiology of PCa.

Methods: National population data from the National Health Insurance Statistical Yearbook and the annual report of national cancer registration and statistics in Korea were assessed. From the data, the incidence, prevalence, and mortality rates of PCa were calculated. The data were presented with reference to other types of cancers occurring in various countries from different continents.

Results: From 2007 to 2013, PCa incidence doubled (from 5,516 per year to 10,855 per year), while its prevalence in Korean men tripled (from 18,830 to 51,411) during the same period. The mortality rate increased slightly, from 4.2 in 2000 to 5.9 in 2007 and 6.0 in 2013 (per 100,000, age adjusted). PCa incidence increased significantly faster in men aged < 70 years than in the older age group.

Conclusion: PCa prevalence in South Korea has increased significantly, mainly due to the rise in its incidence. As the country is facing major changes, including westernization of dietary habits and rapid population aging, its prevalence would continue to increase in near future.

No MeSH data available.


Related in: MedlinePlus